Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.18
GLAXF's Cash to Debt is ranked lower than
52% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.70 vs. GLAXF: 0.18 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.18

Equity to Asset 0.16
GLAXF's Equity to Asset is ranked lower than
55% of the 750 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GLAXF: 0.16 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.16

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
55% of the 484 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.05 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 7
Z-Score: 2.49
M-Score: -2.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 25.27
GLAXF's Operating margin (%) is ranked higher than
94% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.55 vs. GLAXF: 25.27 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 25.27

1.68
36.94
Net-margin (%) 19.32
GLAXF's Net-margin (%) is ranked higher than
93% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.99 vs. GLAXF: 19.32 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 19.32

5.76
23.94
ROE (%) 77.67
GLAXF's ROE (%) is ranked higher than
100% of the 796 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. GLAXF: 77.67 )
GLAXF' s 10-Year ROE (%) Range
Min: 18.39   Max: 253.19
Current: 77.67

18.39
253.19
ROA (%) 12.23
GLAXF's ROA (%) is ranked higher than
95% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.01 vs. GLAXF: 12.23 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.87   Max: 27.12
Current: 12.23

3.87
27.12
ROC (Joel Greenblatt) (%) 62.86
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.22 vs. GLAXF: 62.86 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.07   Max: 93.68
Current: 62.86

5.07
93.68
Revenue Growth (%) -0.90
GLAXF's Revenue Growth (%) is ranked higher than
60% of the 670 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (%) Range
Min: -1.5   Max: 91
Current: -0.9

-1.5
91
EBITDA Growth (%) 17.30
GLAXF's EBITDA Growth (%) is ranked higher than
83% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. GLAXF: 17.30 )
GLAXF' s 10-Year EBITDA Growth (%) Range
Min: -11.8   Max: 85.9
Current: 17.3

-11.8
85.9
EPS Growth (%) 51.40
GLAXF's EPS Growth (%) is ranked higher than
95% of the 624 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.70 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (%) Range
Min: -30.2   Max: 93.9
Current: 51.4

-30.2
93.9
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.80
GLAXF's P/E(ttm) is ranked higher than
95% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 42.90 vs. GLAXF: 14.80 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 14.8

10.16
40.41
P/B 11.35
GLAXF's P/B is ranked higher than
52% of the 828 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.60 vs. GLAXF: 11.35 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.06
Current: 11.35

5.48
14.06
P/S 2.87
GLAXF's P/S is ranked higher than
75% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.72 vs. GLAXF: 2.87 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 2.87

1.94
4.9
PFCF 16.38
GLAXF's PFCF is ranked higher than
95% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 16.38 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 16.38

8.21
41.33
EV-to-EBIT 13.39
GLAXF's EV-to-EBIT is ranked higher than
91% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.14 vs. GLAXF: 13.39 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 13.39

7.7
240.2
PEG 6.21
GLAXF's PEG is ranked higher than
84% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. GLAXF: 6.21 )
GLAXF' s 10-Year PEG Range
Min: 0.23   Max: 99.36
Current: 6.21

0.23
99.36
Shiller P/E 15.99
GLAXF's Shiller P/E is ranked higher than
94% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 121.61 vs. GLAXF: 15.99 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.93   Max: 21.72
Current: 15.99

10.93
21.72
Current Ratio 1.11
GLAXF's Current Ratio is ranked lower than
52% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. GLAXF: 1.11 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 1.11

0.97
1.78
Quick Ratio 0.77
GLAXF's Quick Ratio is ranked lower than
52% of the 650 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. GLAXF: 0.77 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.77

0.68
1.42

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.70
GLAXF's Dividend Yield is ranked higher than
99% of the 482 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. GLAXF: 5.70 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.72
Current: 5.7

2.72
5.72
Dividend Payout 0.81
GLAXF's Dividend Payout is ranked higher than
68% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. GLAXF: 0.81 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.81

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
82% of the 351 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 7.81
GLAXF's Yield on cost (5-Year) is ranked higher than
98% of the 490 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.40 vs. GLAXF: 7.81 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.73   Max: 7.84
Current: 7.81

3.73
7.84
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
90% of the 585 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.30 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 51.8   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.42
GLAXF's Price/DCF (Projected) is ranked higher than
91% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.36 vs. GLAXF: 1.42 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.82   Max: 4.41
Current: 1.42

0.82
4.41
Price/Median PS Value 0.99
GLAXF's Price/Median PS Value is ranked higher than
84% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.25 vs. GLAXF: 0.99 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 2.57
Current: 0.99

0.69
2.57
Earnings Yield (Greenblatt) 7.50
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
87% of the 660 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. GLAXF: 7.50 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 7.5

0.4
12.9
Forward Rate of Return (Yacktman) 6.05
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
80% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. GLAXF: 6.05 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 67.4
Current: 6.05

2.2
67.4

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals including HIV, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, vaccines and dermatologicals. The Company operates in two industry segments: Pharmaceuticals and Consumer Healthcare. The Company's pharmaceutical products include treatments for asthma, HIV/AIDS, malaria, depression, migraine, diabetes, heart failure, digestive conditions and cancer. The Company markets over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. The Company produces medicines that treat six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions. In addition, it is developing new treatments for cancer. The Company's portfolio comprises three main categories: OTC medicines, Oral healthcare and Nutritional healthcare. OTC medicines- alli is the first licensed weight loss medicine to be available without a prescription, launched in the USA in 2007. Oral healthcare- Aquafresh, a range of toothpastes, toothbrushes and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene; Polident, PoliGrip and Corega, the denture care cleansers and adhesives; and Other brands include Odol, Macleans and Dr Best. Nutritional healthcare- Lucozade is a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. The Company has operations in USA, Europe, Asia Pacific, Japan and Canada.
» More Articles for OTCPK:GLAXF

Headlines

Articles On GuruFocus.com
Guru Stocks at 52-Week Lows: BHP, GSK, VOD, LYG, TEF Sep 16 2014 
Guru Stocks at 52-Week Lows: GSK, VOD, LYG, EC, VALE Sep 08 2014 
3 Dividend Kings From The U.K. I Love To Buy Aug 21 2014 
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, MFG Aug 18 2014 
You Should Consider Adding GlaxoSmithKline Based on Tremendous ROE Aug 08 2014 
Widely Held Guru Stocks Near 52-Week Lows Aug 05 2014 
Guru Stocks at 52-Week Lows: PFE, GSK, VOD, EC, UBS Aug 04 2014 
A Look at the Week's Top Dividend Growers Jul 28 2014 
Highest Yielding Stocks Widely Held By The Gurus Jul 01 2014 
Diamond Hill Capital Comments on GlaxoSmithKline PLC Jun 26 2014 

More From Other Websites
Oxford volunteer given experimental vaccine against Ebola Sep 17 2014
First UK volunteer gets experimental GSK Ebola shot in trial Sep 17 2014
First UK volunteer gets experimental GSK Ebola shot in trial Sep 17 2014
Veteran untainted by banking crisis Sep 12 2014
First person in UK trial to get experimental Ebola shot next week Sep 12 2014
Japan's Ajinomoto to buy Windsor Quality for $800m Sep 10 2014
AstraZeneca drug misses goal in severe COPD but improves lung function Sep 08 2014
WHO urges use of blood-derived drugs against Ebola, backs vaccine trials Sep 05 2014
Drug and vaccine makers in race against Ebola Sep 05 2014
Volunteers sought for human trials of Ebola vaccine Sep 05 2014
WHO urges drug companies, regulators to speed Ebola work Sep 04 2014
Nigeria monitoring 400 contacts of doctor who died of Ebola Sep 04 2014
Guinea detects Ebola in new region as U.S. warns outbreak out of control Sep 03 2014
British Ebola patient discharged from hospital after ZMapp treatment Sep 03 2014
India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden Sep 01 2014
Experimental Ebola drug ZMapp cures 100 percent of lab monkeys Aug 29 2014
FTSE inches higher, Tesco slumps after profit warning Aug 29 2014
Ukraine tensions pull US stocks modestly lower Aug 28 2014
West Africa Ebola outbreak could infect 20,000 people, WHO says Aug 28 2014
Gene studies of Ebola in Sierra Leone show virus is mutating fast Aug 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK